Slide 1: Embecta Corp. Diabetes Considerations November 2023
Embecta Corp. Diabetes Considerations November 2023
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statemen
Slide 3: Market Overview
Market Overview © embecta’
Slide 4: Diabetes is a large and growing disease; the impact is felt around the globe
4 Diabetes is a large and growing disease; the impact is felt around the globe Prevalence: 537M; people with diabetes using insulin: ~65M to ~70M1,2 *PWD = People with diabetes References 1 Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee . IDF DIABETES ATLAS. 10th edition
Slide 5: References
5 References 1 CDC. Prevalence of Prediabetes Among Adults. Published August 7, 2020. Updated September 30, 2022. Accessed February 7, 2023. https://www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html 2 Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committe
Slide 6: Type 1 Diabetes
Type 1 Diabetes © embecta’
Slide 7: T1D results from an autoimmune response that destroys insulin-producing beta cells
7 T1D results from an autoimmune response that leads to destruction of insulin-producing beta cells in the pancreas2-4 • When the autoimmune process starts, people will typically have normal blood glucose levels • It may take months to years to develop abnormal blood sugars • A clinical diagnosis of
Slide 8: Type 2 Diabetes
Type 2 Diabetes © embecta’
Slide 9: T2D results from a combination of genetic, environmental and lifestyle factors
9 T2D results from a combination of genetic, environmental and lifestyle factors2,3 • T2D accounts for over 90% of all diabetes worldwide • In the prediabetes stage, the body is producing more endogenous insulin to overcome insulin resistance, which over time leads to beta cell exhaustion • When the
Slide 10: GLP-1 RA and GLP-1 RA/GIP Therapies
10 GLP-1 RA and GLP-1 RA/GIP Therapies
Slide 11: GLP-1 RA and GLP-1 RA/GIP therapy are treatment options for type 2 diabetes, not a cure
11 GLP-1 RA and GLP-1 RA/GIP therapy are treatment options for type 2 diabetes, not a cure. These therapies:3,4 • are known to improve glycemic control and promote weight loss • can be used in combination with other diabetes medications including insulin in type 2 diabetes • may reduce the risk of s
Slide 12: Many people with type 2 diabetes will eventually require and benefit from insulin therapy
12 Many people with type 2 diabetes will eventually require and benefit from insulin therapy1-5 • While GLP-1 RA therapy helps control blood glucose levels, benefits may decline over time due to the progressive nature of the disease • GLP-1 RA therapy has optimum benefit in people with diabetes who
Slide 13: Market Considerations & Opportunity
13 Market Considerations & Opportunity
Slide 14: Insulin prescription trends remain stable
14 • Weekly GLP-1 RA drugs have been marketed for several years • Over that time, insulin prescription trends in the United States have remained relatively consistent demonstrating that insulin remains an important treatment option for type 2 diabetes even with the availability of GLP-1 RA therapies
Slide 15: embecta's insulin injection revenue remained stable while new treatments entered the market
15 International 46%US 54% embecta’s insulin injection revenue remained stable even while multiple new treatments for type 2 diabetes entered the market $0 $200 $400 $600 $800 $1,000 FY17 FY18 FY19 FY20 FY21 FY22 FY23 Re ve nu e (in m ill io ns ) FY23 Global Revenue FY17-FY23 US Revenue CAGR: 1.2% U
Slide 16: GLP-1 RA therapies are delivered via pens/pen needles, vials/syringes and autoinjectors
16 GLP-1 RA and GLP-1 RA/GIP therapies are delivered via pens/pen needles, vials/syringes and autoinjectors Our pen needles are compatible with widely used pen injector devices including those marketed by a variety of companies including1* embecta has segment leadership in diabetes injection device
Slide 17: Significant opportunity exists to help people living with diabetes
17 Significant opportunity exists to help people living with diabetes • Since our pen needles are compatible with widely used pen injector devices, we continue to actively explore opportunities with companies developing generic GLP-1 RA therapies to co-package or co-promote with our pen needles • em